Eben Tessari - 01 Apr 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
01 Apr 2023
Net transactions value
$0
Form type
4
Filing time
03 Apr 2023, 16:30:26 UTC
Previous filing
20 Mar 2023
Next filing
11 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Award $0 +42,544 $0.000000 42,544 01 Apr 2023 Class A Common Share 42,544 $10.76 Direct F1
transaction KNSA Restricted Share Unit Award $0 +7,091 $0.000000 7,091 01 Apr 2023 Class A Common Share 7,091 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2023.
F2 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F3 The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023.